Compare CATY & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CATY | NAMS |
|---|---|---|
| Founded | 1962 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | N/A | N/A |
| Metric | CATY | NAMS |
|---|---|---|
| Price | $50.24 | $31.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $50.80 | $46.40 |
| AVG Volume (30 Days) | 424.4K | ★ 764.0K |
| Earning Date | 01-22-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | ★ 9.40 | N/A |
| EPS | ★ 4.33 | N/A |
| Revenue | ★ $711,617,000.00 | $35,243,000.00 |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $8.37 | $10.46 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $36.06 | $14.06 |
| 52 Week High | $51.95 | $42.00 |
| Indicator | CATY | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 34.65 |
| Support Level | $48.74 | $30.97 |
| Resistance Level | $51.32 | $32.45 |
| Average True Range (ATR) | 1.08 | 1.59 |
| MACD | 0.03 | -0.29 |
| Stochastic Oscillator | 69.62 | 17.72 |
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.